Role of dynamic contrast-enhanced and diffusion weighted MRI in evaluation of necrosis of hepatocellular carcinoma after chemoembolization  by Osama, Reham M. et al.
The Egyptian Journal of Radiology and Nuclear Medicine (2013) 44, 737–746Egyptian Society of Radiology and Nuclear Medicine
The Egyptian Journal of Radiology andNuclearMedicine
www.elsevier.com/locate/ejrnm
www.sciencedirect.comORIGINAL ARTICLERole of dynamic contrast-enhanced
and diﬀusion weighted MRI in evaluation
of necrosis of hepatocellular carcinoma after
chemoembolizationAbbreviations: TACE, transarterial chemoembolization; CT, com-
puted tomography; RECIST, response evaluation criteria in solid
tumors; DCE MRI, dynamic contrast enhanced magnetic resonance
imaging; ADC, apparent diffusion coefﬁcient; THRIVE, high resolu-
tion isotropic volume examination; DWI, diffusion weighted imaging;
GRAPPA, parallel imaging with generalized auto- calibrating partially
parallel acquisition; ROI, region of interest; TSE, turbo spine echo;
FFE, fast ﬁeld echo.
* Corresponding author. Tel.: +20 1006886270.
E-mail address: reham81_2006@hotmail.com (R.M. Osama).
Peer review under responsibility of Egyptian Society of Radiology and
Nuclear Medicine.
Production and hosting by Elsevier
0378-603X  2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear Medicine.
http://dx.doi.org/10.1016/j.ejrnm.2013.09.012Open access under CC BY-NC-ND license.Reham M. Osama a,*, Ahmed H.K. Abdelmaksoud a, Sanaa A.M. El Tatawy a,
Mohammed M. Nabeel b, Lamia I.A. Metwally aa Department of Radiology, Faculty of Medicine, Cairo University, Egypt
b Department of Endemic Medicine and Hepatology, Faculty of Medicine, Cairo University, EgyptReceived 17 June 2013; accepted 25 September 2013
Available online 23 October 2013KEYWORDS
Dynamic MRI;
Diffusion-weighted;
TACE;
Hepatocellular carcinomaAbstract Purpose: The purpose of this study is to evaluate the role of dynamic contrast enhanced
and diffusion weighted MRI in the assessment of response and necrosis in the treatment of hepa-
tocelluar carcinoma after transcatheter arterial chemoembolization (TACE).
Subjects and methods: Precontrast T1, T2, STIR, Dynamic contrast enhanced and respiratory trig-
gered diffusion weighted MR images (b factor, 500, 1000 s/mm2 obtained in 50 patients with hepa-
tocellular carcinoma who underwent transarterial hepatic chemoembolization). Diffusion-weighted
MR images, gadolinium-enhanced MR images after TACE were assigned conﬁdence levels for post-
operative HCC recurrence. The sensitivity, speciﬁcity, PPV, NPV and overall agreement were cal-
738 R.M. Osama et al.culated for both the dynamic and the DWI images. Apparent diffusion coefﬁcients (ADCs) were
calculated searching for a cut off value using the ROC curve.
Results: Dynamic MRI had a sensitivity of 90.5%, a speciﬁcity of 96.6%, a positive predictive
value of 95%, a negative predictive value of 93.3% and an overall agreement of 94% compared
to 100%, 65.5%, 67.7%, 100% and 80% respectively of diffusion weighted imaging.
The difference between the malignant and benign groups’ ADC variables was statistically signiﬁcant
P value 0.006.
The ROC curve showed that the area under the curve is C= 0.728 with SE = 0.075 and 95% CI
from 0.582 to 0.874.
Conclusion: Diffusion weighted MR imaging has lower speciﬁcity compared to dynamic MRI with
increased false positives. We suggest that increase is due to intralesional hemorrhage or liquefactive
necrosis causing diffusion restriction. Diffusion weighted imaging may act as a supplementary
sequence to compensate the dynamic MRI in patients who could not hold their breath adequately.
 2013 Production and hosting by Elsevier B.V. on behalf of Egyptian Society of Radiology and Nuclear
Medicine. Open access under CC BY-NC-ND license.1. Introduction
With the expanded use of locoregional therapies as a corner-
stone in the treatment of tumors of multiple organs, it became
indispensible to implement new radiological techniques to pro-
vide patients with more efﬁcient follow up.
TACE affects the tumor to the maximum impact of chemo-
therapy by selective or superselective injection of tumor vessels
by chemotherapeutic agents and reducing the tumoral blood
ﬂow by the embolization of particles resulting in prolonged
contact of the tumor with the chemotherapeutic agents (1).
Lipiodol is used as a carrier for the chemotherapeutic agents.
It slowly reaches the sinusoids and then gets trapped within
the tumor vessels that lack kupffer cells (2).
CT is still the examination of choice to follow up patients
being performed immediately after the TACE procedure to en-
sure the retention of lipiodol by the tumor. It is repeated
1 month later for the detection of any tumoral residue or
recurrence.
A diagnostic dilemma due to defective accumulation of lip-
idol either due to necrotic areas or residual tumor is still faced
by radiologists. Also the hyperattenuating retained lipidol
causes hardening artifact which degrades the interpretation
of images (Fig. 1) (3).
Standardized criteria (RECIST) were still defective for
monitoring the response to therapy, and this is attributed to
the fact that such treatments may not lead to early regression
of tumor volume, but rather an increase in the extent of tumor
necrosis (4).
Takayasu et al. (5) concluded in their study that there is no
correlation between tumor size reduction and the histopatho-
logic necrosis rate in the resected specimens. Such a study ex-
plains the lack of this correlation by the delayed resorption of
necrosis when the artery and sinusoid feeding the tumor are
completely embolized and occluded.
Therefore, it has been recommended to modify the RE-
CIST criteria to take into account only the diameters of the
viable areas of the target lesions (i.e., the regions of tumors
showing contrast enhancement during the arterial phase).
However, the accurate measurement of lesion size is still difﬁ-
cult due to the wide variations between interpreters in estimat-
ing the position of the lesion edges. This is crucial especially in
inﬁltrating tumors, in tumors containing irregular areas ofnecrosis or when small satellite lesions are surrounding the
main tumor (4).
Besides, the surrounding post-treatment edematous
changes could give rise to an apparent increase in size. Thus,
change in tumor volume is not an indicator to predict the his-
tological tumor response (6).
MRI allows the detection of anatomic, functional and
molecular parameters in order to assess the response to treat-
ment. Non-contrast T1- and T2-weighted images provide
information concerning the morphological changes, changes
in the ﬂuid content and ﬁbrosis. As for the dynamic contrast
enhanced MRI (DCE MRI), it provides information regarding
the tumoral perfusion (7). Contrast-enhanced MRI is sensitive
to therapy-related changes in blood volume and vascular per-
meability which may be associated with tumor angiogenesis
(8).
Diffusion weighted image provides an insight about water
composition within a tumor and assessing the degree of tumor
viability. The viable tumor cells have intact membranes that
cause restricted water diffusion whereas necrotic tumors have
increased water diffusion due to cell membrane disruption (9).
The apparent diffusion coefﬁcient (ADC) calculated in dif-
fusion-weighted MRI has become a good aiding biomarker of
tumor response to therapy. The ADC is a measure of the
mobility of water within tissues. The viable tumors are highly
cellular, and the cells have an intact cell membrane that re-
stricts the mobility of the water molecule resulting in a rela-
tively low ADC. Conversely, the cellular necrosis increases
membrane permeability, allowing free mobility of water mole-
cules and causing an increase in ADC (10).
2. Subjects and methods
2.1. Patients
This study included 50 cases of HCC who underwent TACE.
The study was conducted in the Kasr Al-Ainy Hospital. The
patients were referred from the Tropical Department to the
Radiology Department over a period of 18 months (June
2011–December 2012).The patients’ age ranged from 40 to
79 years (median 60);42 patients were males and 8 were fe-
males. All patients had liver cirrhosis related to chronic viral
hepatitis.
Fig. 1 The effect of hardening artifact on the interpretation of CT ﬁndings. (A) arterial phase contrast enhanced CT of a 60 year old
male showing a well deﬁned right hepatic lobe (segment VI) heterogenously enhancing mosaic HCC. (B) Post TACE arterial phase
contrast enhanced CT of the same patient showing type II lipidol accumulation within the tumor; partial defect in the tumor; with
difﬁculty to detect residual enhancing portions due to hardening artifact. (C–E) Dynamic MRI of the same patient (C) Early arterial phase
of T1 THRIVE (High Resolution Isotropic Volume Examination), (D) Corresponding subtraction image and (E) Corresponding relative
enhancement color mapping image. They show clearly the residual enhancing portions without being affected by the lipiodol signal.
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All patients were examined in our multidisciplinary clinic. The
procedure started by the Siledenger technique through the
right femoral artery followed by catheterization of the com-
mon and proper hepatic arteries. Super-selective catheteriza-
tion of the feeding artery was done in most of the cases
using a micro-catheter then an injection of a mixture of Lipi-
odol and Adriamycin was injected.2.1.2. MRI
MRI was performed using 1.5-T MRI scanner (Philips Intera)
equipped with phased-array torso surface coil.
 Examination included precontrast axial T1, T2 and SPIR
weighted images, coronal T1 and T2, dynamic and Diffu-
sion MRI.
 Dynamic study was performed after bolus injection of
0.1 mmol/kg body weight of Gd-DTPA at a rate of
2 ml/s, ﬂushed with 20 ml of sterile saline solution via the
antecubital vein. The injection of contrast medium and
saline solution was performed manually.
 Dynamic imaging using T1 THRIVE (High Resolution Iso-
tropic Volume Examination) technique was performed in
triphasic way; A dynamic series consisted of one pre contrast
series followed by four successive post contrast series includ-
ing early arterial, late arterial, and portal phase imaging with18–21 s intervals (including 17–20 s for image acquisition
with breath-holding according to liver size and 1 s for re-
breathing for the start of each phase imaging) followed by
5-min delayed phase imaging. Image acquisition starts after
contrast injection by 10 s. All patients were imaged in end
expiration to limit the risk of image misregistration.
 DWI was performed before the dynamic imaging using
respiratory triggered fat suppressed single-shot echoplanar
sequence that combined the two diffusion (motion-probing)
gradients before and after the 180 pulse along the three
directions of section-select, phase-encoding, and fre-
quency-encoding and data acquisition with EPI readout.
It was obtained by applying three different b factors of 0,
500, and 1000 s/mm2.
 Parallel imaging with generalized auto- calibrating partially
parallel acquisition (GRAPPA) with an acceleration factor
of two was applied to reduce the acquisition time.
2.2. MR images were analyzed for the following
1. Size and border of the lesion.
2. The T1, T2 and FAT SATURATED signal characteristics.
3. Pattern of enhancement in the dynamic imaging, subtracted
images, and color mapping. For interpretation of the
dynamic imaging, arterial hypervascularity and subsequent
washout appearance were regarded as suggestive ﬁndings of
Table 1 Represents the various maximum diameters of the
tumors in cm.
Malignant Benign Dimension
1.7 1.5 Minimum
6 8.5 Maximum
3.52 ± 1.30 3.8 ± 1.90 Mean ± SD
740 R.M. Osama et al.viable HCC. Meanwhile benign conditions were considered
when progressive or persistent enhancement was detected
on dynamic images.
4. Signal intensity on diffusion images with ADC values
and fusion images using a commercially windows work-
station (PHILIPS).The pattern of diffusion
restriction was classiﬁed into- heterogeneous, rim and
focal nodular.
 All DWI images using different b values were sorted for the
conﬁdence levels according to three grade scales:-
(1) Benign conditions were considered when lost signal on
diffusion images or mild sustained hyperintensity with
bright ADC map (shine through effect) is noted.
(2) Uncertainty is considered when sustained faint or mod-
erate hyperintensity is seen on diffusion images with iso-
intensity on ADC maps.
(3) Viable tumor portion was identiﬁed by sustained hyper-
intensity in the diffusion images compared with the sig-
nal drop of background parenchyma with increasing b
values combined with low ADC map.
 Intensity on diffusion images was classiﬁed mild-moderate-
marked compared to the spinal cord on b value 1000.
2.3. ADC measurement
 Pixel-based ADC maps were generated on the workstation.
ADC was calculated with linear regression analysis of the
function S= S0 · exp (b · ADC), where S is the signal
intensity after application of the diffusion gradient, and S0
is the signal intensity at a b value of 0 s/mm2. The three b val-
ues (0, 500, and 1000 s/mm2) were used for ADC calculation.
 For precise placement of circular ROI in the small
lesions, the center of the lesion on the DWI was deter-
mined by the interfacing point of two lines met at right
angles which are a vertical line and a horizontal line from
the upper and the left border of the images, respectively.
With the knowledge of the length of each line, the iden-
tical lines could be drawn on the corresponding ADC
map. With the reference of the lesion size on DWI, circu-
lar ROI was placed around the center point to measure
the ADC of the lesion.
 A region of interest was drawn over any sustained hyperinten-
sity areas on diffusion images, and if no high signal could be
identiﬁed, the whole lesionwasmeasured. TheADCwasmea-
sured three times and the three measurements were averaged.
2.4. Statistical analysis
 Computer software package SPSS version 15 was used in
the analysis.
 For quantitative variables, mean (as a measure of central
tendency), and standard deviation (as measures of variabil-
ity) were presented.
 Frequency and percentages were presented for qualitative
variables.
 Chi-Square test was used to estimate differences in qualita-
tive variables.
 A ROC (Receiver Operating Characteristic) curve was con-
structed and the area below the ROC curve was used to rep-
resent prediction precision. P-values less than 0.05 were considered as statistically
signiﬁcant.2.5. The standard of reference
 It was difﬁcult to obtain pathologic conﬁrmation in patients
who underwent chemoembolization because most of these
patients do not undergo surgery. In addition, biopsy may
result in sampling error.
- Residual/recurrent HCC was ﬁnally diagnosed depending
on the follow-up imaging ﬁndings including further tumor
growth or sustained iodized-oil accumulations in the hyper-
vascular area on the hepatic arteriography with repeated
TACE.
- In the benign conditions involving the perilesional hepatic
parenchyma such as inﬂammatory, ischemic changes, or
pseudolesions. The perilesional abnormal signal intensity
area should disappear or decrease in size on MRI in
3 months follow-up.
3. Results
 Twenty-one out of the ﬁfty patients had local tumor recur-
rence (Figs. 1 and 3).
 The size of chemoembolized lesions ranged from1.5 to 8.5 cm.
the maximum, minimum, mean and standard deviation of
both malignant and benign groups are illustrated in Table 1.
 Among the 50 patients included in our study, 32% of
lesions showed heterogenous signal intensity and 10% of
the benign group lesions exhibited high T2 signal intensity
that makes an assessment of HCC necrosis after TACE
based on precontrast sequences signal intensity a conﬂict
issue (Figs. 2, 4 and 5).
 In 86% of benign conditions the lesion border was circular
compared to 52.3% of residual lesions.
Dynamic MRI had a sensitivity of 90.5%, a speciﬁcity of
96.6%, a positive predictive value of 95%, a negative predic-
tive value of 93.3% and an overall agreement of 94% com-
pared to 66.7%, 72.4%, 63.6%, 75% and 70% respectively
in diffusion weighted imaging. If we regarded the scale 2 as a
positive interpretation, the overall sensitivity of diffusion
weighted imaging increased from 66.7% to 100% while the
speciﬁcity decreased from 72.4% to 65.5% (Table 2).
 Regarding the pattern of diffusion restriction, 76.2% of
true positive cases seen with diffusion weighted imaging
exhibited focal peripheral nodular restriction, meanwhile
60% of the false positive cases exhibited intralesional heter-
ogeneous restriction (Figs. 3 and 5)
Fig. 2 Typical signal pattern of chemoembolized HCC. (A)
Axial T1 FFE showing the typical high signal intensity of the right
hepatic lobe (segment VI) chemoembolized HCC. (B) Coronal T2
TSE of the same patient showing the typical low signal intensity of
the right hepatic lobe (segment VI) chemoembolized HCC. (C)
Axial SPIR of the same patient showing the typical low signal
intensity of the right hepatic lobe (segment VI) chemoembolized
HCC.
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ADC variables was statistically signiﬁcant with a P value
of 0.006.
 The ROC curve (Fig. 6) was obtained by plotting ADC
variables at different cut off values. A statistical software
estimated the area under the curve to be C= 0.728 with
SE = 0.075 and 95% CI from 0.582 to 0.874.
 It seems from the ROC that the ADC variable is a fair indi-
cator to differentiate marginal recurrence of HCC from per-
ilesional benign lesions. The best cut off value thatmaximizes (sensitivity and speciﬁcity) is 1.26 mm2/s. At this
ADC value, the sensitivity is 95% and speciﬁcity is 59%
(1speciﬁcity = 0. 41)
4. Discussion
MRI provides anatomic details, as well as functional and
molecular parameters for the assessment of the response of
HCC to treatment. Authors stated that the successful tumoral
treatment after TACE results in diminished blood supply with
subsequent diminished tissue ﬂuid. Thus the typical post treat-
ment appearance is high signal intensity on T1-weighted
images and low signal intensity on T2-weighted images (11–
13).
Among the 50 patients included in our study, about 32% of
lesions showed heterogenous signal intensity that makes an
assessment of HCC necrosis after TACE based on precontrast
sequences signal intensity a conﬂict issue. Also, it was reported
that T2 hyperintensity not only represents residual tumor but
also could represent hemorrhage, liquefactive necrosis, or
inﬂammatory inﬁltrate (1). Therefore, it was difﬁcult to assess
the viable HCC tumors after TACE by conventional spin echo
imaging. In our study 10% of the benign group lesions exhib-
ited high T2 signal intensity.
Contrast-enhanced MRI is sensitive to therapy-related
changes in blood volume and vascular permeability which
may be associated with tumor angiogenesis (8). Braga et al.
(12) stated that Dynamic MRI for unsuccessful TACE treat-
ment shows focal enhanced regions admixed within non
enhancing necrotic areas.
However, it was mentioned that the perilesional hypervas-
cularity depicted by dynamic MRI is not speciﬁc only for the
recurrent lesions but also occurs in benign conditions as a re-
sult of adjacent inﬂammation or other non tumorous arterio-
portal shunts, including direct arterioportal ﬁstula or
decreased portal venous ﬂow related to iatrogenically induced
portal tract injuries in the territory of selective TACE (14,1).
It was stated that benign conditions should show a perile-
sional rind-like contour and hyperintensity on delayed phase
postcontrast images, meanwhile the residual lesions have more
nodular contour and washout of the contrast medium on the
delayed phase (15,16).
In the experience of Kim et al. (17) image subtraction was
helpful for the assessment of the therapeutic efﬁcacy for
HCC by TACE in HCCs, which makes the depiction of tumor
enhancement difﬁcult on post-contrast T1-weighted images.
Accordingly, to accurately assess tumor enhancement, we used
the image subtraction techniques as well as color mapping
images.
In our study, we had relatively lower sensitivity of dynamic
MRI compared to other studies as we had two cases in which
inappropriate breath holding led to motion artifact with subse-
quent false interpretation by the viewer. We had also one false
positive case due to misinterpretation of a perilesional arterio-
portal shunt.
Diffusion-weighted imaging gives an insight about water
content within a tumor and the degree of its viability. The via-
ble tumor cells have intact membranes that cause restricted dif-
fusion whereas necrotic tumors have increased water diffusion
due to disruption of the cell membrane (18,19).
Fig. 3 Residual HCC. (A) Axial T1 FFE of 45 year old male with hepatitis C showing heterogenous predominantly high signal intensity
of the right hepatic lobe chemo- embolized HCC. Note the medial hypointense medial portion of the lesion (arrowed). (B) Axial T2 TSE of
the same patient showing heterogenous signal intensity of the lesion with high signal intensity of its medial portion (arrowed). (C and D)
axial early arterial phase of T1 THRIVE and corresponding maximum relative enhancement of the same patient showing early arterial
enhancement of the medial residual portion. (E and F) Diffusion weighted imaging (b value 1000) and the corresponding ADC showing
restricted diffusion of the medial portion of the lesion with ADC value of 1.18 ± 0.91.Note the nodular pattern of diffusion restriction.
(G) Fusion image showing overlap between the high signal intensity medial portion of the lesion on T2 WIs and the restriction seen on
diffusion images (b value 1000).
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Fig. 4 complete ablation of caudate lobe HCC. (A) Axial T1 FFE of 56 year old male showing heterogenous signal intensity of a caudate
lobe chemo-embolized HCC. (B) Axial T2 SSh of the same patient showing central core of high signal intensity with peripheral rim of low
signal intensity. (C) Axial early arterial phase of T1 THRIVE showing faint peripheral rim enhancement. (D) Axial post contrast T1FFE
showing progressive increase of the uniform peripheral rim of enhancement. (E) Axial respiratory triggered diffusion weighted image (b
value 1000) showing faint uniform peripheral rim of high signal intensity. (F) Non contrast CT of the same patient showing dense lipiodol
uptake by the tumor.
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sponded to chemoembolization treatment showed a signiﬁcant
rise in the ADC values after treatment (20–22,6). Interestingly,
a signiﬁcant rise in the ADC values following TACE in pa-
tients with HCC could be detected as early as 12–24 h after
therapy in patients who were subsequently deﬁned as respond-
ers by RECIST criteria (23).
Practically, however, Yu et al. stated that it is more impor-
tant to know whether the procedure was complete or incom-
plete rather than calculating ADC values before and after
the procedure. They measured the ADC value to differentiate
between the marginal recurrences of HCC from perilesionalbenign conditions. They found that the ADC values varied
widely for the nontumorous lesions and grossly overlapped
with the viable tumor portion making it impossible to deter-
mine any cutoff points.
They reported that DWI increased the sensitivity for the
detection of post TACE residual HCC with increased false
positives. Thus, the decreased speciﬁcity compromised the in-
creased sensitivity gained by DWI and decreased the overall
diagnostic accuracy. They referred the increase in false positive
ﬁndings to perilesional parenchymal insults that showed sus-
tained hyperintensity on DWI with increasing b factors. They
demonstrated that hypercellularity intermingled with a ﬁbrotic
Fig. 5 Complete ablation of HCC with newly detected HCC nodule. (A) Axial T1 FFE of 60 year old male shows heterogenous signal
intensity of a left hepatic lobe (segment II) chemo-embolized HCC (arrowhead). Note the left hepatic lobe (Segment IVb) high signal
intensity dysplastic nodule (arrowed) with faint hypointensity of its medial portion(nodule with nodule sign). (B) Axial T2 ssh of the same
patient showing heterogenous signal intensity of the left hepatic lobe (segment II) chemo-embolized HCC (arrowhead). Note the reversal
of signal intensity of the segment IVb lesion with the dysplastic nodule exhibiting low signal compared to the high signal of the medial
HCC nodule. (C) Axial early arterial phase of T1 THRIVE showing peripheral rim enhancement in segment II chemoembolized lesion.
Note the heterogenous enhancement of the segment IVb focal lesion. (D) Axial delayed phase of T1 THRIVE showing progressive
increase of the peripheral rim of enhancement of segment II chemoembolized lesion. Note the wash out of the medial HCC nodule of
segment IVb lesion with near isointensity of the lateral dysplastic nodule. (E and F) Axial respiratory triggered diffusion weighted image (b
value 1000) and the corresponding ADC showing heterogenous marked restriction of the chemoembolized HCC.
744 R.M. Osama et al.content in the inﬂammatory granulation tissue could cause re-
stricted diffusion, resulting in sustained hyperintensity on
DWI.
In our study, 10 false positive cases out of 50 patients were
misdiagnosed on diffusion weighted imaging. When we re-
viewed the corresponding pattern of diffusion restriction,
76.2% of true positive cases exhibited focal peripheral nodular
restriction, meanwhile 60% of the false positive cases exhibited
intralesional heterogenous restriction (Fig. 6). So, we consid-ered that the increase in false positive ﬁndings in our study is
likely originating from intralesional hemorrhage or liquefac-
tive necrosis that causes diffusion restriction. In the studies
of Holtas et al., Tung et al., Batra et al. (24–26) sterile liquefac-
tive necrosis and intracavitary microhaemorrhage are accepted
to be the cause of hyperintensity in diffusion-weighted MR
images of malignant necrotic lesions.
Our results are matching with those of yu et al. and Goshi-
ma et al. (27) showing dynamic contrast enhanced MRI to be
Table 2 Diagnostic indices (sensitivity, speciﬁcity, PPV, NPV
and overall agreement) of dynamic and diffusion MRI in the
studied group.
DWI (%) Dynamic mri (%)
100 90.5 Sensitivity
65.5 96.6 Speciﬁcity
67.7 95 PPV
100 93.3 NPV
80 94 Overall agreement
1 - Specificity
1.00.80.60.40.20.0
Se
ns
it
iv
it
y
1.0
0.8
0.6
0.4
0.2
0.0
ROC Curve
Diagonal segments are produced by ties.
Fig. 6 Results of receiver operating curves for ADC values in
distinguishing benign and malignant groups.
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sponse to treatment.
Diffusion weighted MRI has some advantages compared to
dynamic MRI. First, contrast medium administration is not
required, and the examination is obtained in a relatively short
time. Second, the technique is easy to be repeated, allowing
close follow-up during and after tumor treatment. Also, image
post-processing is less time-consuming compared to dynamic
contrast-enhanced MR imaging. At last, Diffusion-weighted
MR imaging allows easy evaluation of the whole tumor. This
is important because of the inhomogeneity that may occur
within tumors (28).
In addition, respiratory triggered diffusion weighted images
compensated the false results by the dynamic MRI in our pa-
tients who could not hold their breath adequately.
In our study, we had some diagnostic limitations. First, it
was difﬁcult to obtain pathologic conﬁrmation in patientswho underwent chemoembolization because all of these pa-
tients were not subjected to surgery. Second, lesions included
in our study were larger than 1 cm in diameter and a few of
them were located at the hepatic dome. The aformentioned
factors could cause selection bias leading to increased sensitiv-
ity of diffusion weighted images, since hepatic lesions close to
the diaphragm pose a challenge to DW-MRI evaluation, as
they are more sensitive to motion, susceptibility artefacts, as
well as artefacts arising from the heart.
In conclusion, in our study, we found that complementary
dynamic and diffusion MRI achieve effective monitoring of tu-
mor response to therapy.
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